anthralin has been researched along with tacrolimus in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Jiang, H; Kato, R; Yamamoto, S | 1 |
| Lewis, HM | 1 |
| Burger, PM; Goos, M; Nussbaum, G; Ockenfels, HM; Schultewolter, T | 1 |
| Laffitte, E; Thielen, AM | 1 |
| Stein Gold, LF | 1 |
3 review(s) available for anthralin and tacrolimus
| Article | Year |
|---|---|
Therapeutic progress. II: Treatment of psoriasis.
Topics: Administration, Topical; Adrenal Cortex Hormones; Anthralin; Calcitriol; Coal Tar; Combined Modality Therapy; Cyclosporine; Dermatologic Agents; Emollients; Humans; Immunosuppressive Agents; Methotrexate; Phototherapy; Psoriasis; Retinoids; Tacrolimus; United Kingdom | 1994 |
[Topical treatments for psoriasis in 2009].
Topics: Administration, Cutaneous; Anthralin; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Drug Therapy, Combination; Emollients; Humans; Keratolytic Agents; Nicotinic Acids; Ointments; Psoriasis; PUVA Therapy; Quality of Life; Tacrolimus; Treatment Outcome; Vitamins | 2009 |
Topical Therapies for Psoriasis: Improving Management Strategies and Patient Adherence.
Topics: Administration, Cutaneous; Anthralin; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Drug Therapy, Combination; Evidence-Based Medicine; Glucocorticoids; Humans; Nicotinic Acids; Patient Compliance; Pharmaceutical Vehicles; Practice Guidelines as Topic; Psoriasis; Quality of Life; Severity of Illness Index; Tacrolimus; Treatment Outcome; Vitamin D | 2016 |
4 other study(ies) available for anthralin and tacrolimus
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Inhibition of anthralin-caused skin tumor promotion and interleukin-1 alpha production by potent immunosuppressant FK506.
Topics: Administration, Topical; Animals; Anthralin; Anticarcinogenic Agents; Carcinogens; Female; Interleukin-1; Mice; Skin Neoplasms; Tacrolimus | 1994 |
Cyclosporin A, FK506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes.
Topics: Anthralin; Cell Line; Cyclosporine; Humans; Immunohistochemistry; Indoles; Intracellular Fluid; Keratinocytes; Organ Culture Techniques; Phosphorylation; Phosphotyrosine; Protein Kinase C; Protein-Tyrosine Kinases; Proteins; Psoriasis; Signal Transduction; Skin; Tacrolimus; Tyrosine | 1995 |